Intranasal vaccination of mice against infection with Mycobacterium tuberculosis.
The intranasal (i.n.) route of immunisation, has recently been of active interest in endeavours to improve the efficacy of vaccination against a number of respiratory infections. Here, we examined the outcome of tuberculous infection in BALB/c mice. I.n. application of the BCG-Pasteur strain was found to be highly protective against challenge infection with the pathogenic H37Rv strain given after a 4-week interval, reflected by the 100-fold reduction of CFUs in both lungs and spleens. Vaccination with the recombinant PstS-1 antigen and cholera toxin significantly protected against the challenge given 10 days later, but only marginally after 12 weeks. Histological examination showed, that i.n. vaccination abrogated the confluent infiltration of lungs with inflammatory cells, which surrounds the granulomas in H37Rv challenged control mice. In conclusion, the strong protection demonstrated by BCG suggests that the i.n. route of vaccine delivery deserves further attention toward improving vaccination against tuberculosis.
Falero-Diaz
G
G
Department of Oral Medicine & Pathology, GKT School of Medicine & Dentistry, Kings College London at Guy's Hospital, London, UK.
Challacombe
S
S
Banerjee
D
D
Douce
G
G
Boyd
A
A
Ivanyi
J
J
D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001500:BCG Vaccine / Q000008:administration & dosage*; D005260:Female; D008168:Lung / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D014376:Tuberculosis / Q000473:pathology / Q000517:prevention & control*; D014611:Vaccination
D000907:Antibodies, Bacterial; D001500:BCG Vaccine